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We applied multiplex-tandem PCR (MT-PCR) to 255 EDTA whole-blood specimens, 29 serum specimens,
and 24 plasma specimens from 109 patients with Candida bloodstream infection (candidemia) to determine
whether a diagnosis could be expedited in comparison with the time to diagnosis by the use of standard blood
culture. Overall, the MT-PCR performed better than blood culture with DNA extracted from whole blood from
52/74 (70%) patients, accelerating the time to detection (blood culture flagging) and determination of the
pathogenic species (by use of the API 32C system [bioMe´rieux, Marcy l’Etoile, France]) by up to 4 days (mean,
2.2 days; range, 0.5 to 8 days). Candida DNA was detected more often in serum (71%) and plasma (75%) than
in whole blood (54%), although relatively small numbers of serum and plasma specimens were tested. The
sensitivity, specificity, positive predictive value, and negative predictive value of the assay with whole blood
were 75%, 97%, 95%, and 85%, respectively. Fungal DNA was not detected by MT-PCR in 6/24 (25%) whole-
blood samples drawn simultaneously with the positive blood culture sample. MT-PCR performed better with
whole-blood specimens stored at 20°C (75%) and when DNA was extracted within 1 week of sampling (66%).
The molecular and culture identification results correlated for 61 of 66 patients (92%); one discrepant result
was due to misidentification by culture. All but one sample from 53 patients who were at high risk of
candidemia but did not have proven disease were negative by MT-PCR. The results demonstrate the good
potential of MT-PCR to detect candidemia, to provide Candida species identification prior to blood culture
positivity, and to provide improved sensitivity when applied to with serum and plasma specimens.
Fungal bloodstream infections (BSIs) are major causes of
morbidity and mortality in hospitalized patients, including crit-
ically ill individuals. Candida spp. rank as the third most com-
mon cause of nosocomial BSIs in the United States (39) and
the eighth most common cause of all BSIs in Australia and
Europe (3, 5). The outcomes of candidemia are poor, with the
crude mortality rate being 40% (28) and the attributable mor-
tality rate being 25 to 49% (10). Other consequences include
excess hospital stay and costs estimated to be U.S. $40,000 per
episode (7, 25).
The early initiation of targeted antifungal therapy is essen-
tial for improving patient outcomes (8, 26). However, the di-
agnosis of fungemia by blood culture, the current “gold stan-
dard,” is slow and insensitive, as yeasts are not detected in
50% of patients with candidemia and molds are rarely re-
covered (15). In addition, 1 to 2 days is required for isolation
and phenotype-based identification from cultures. A number
of alternative techniques, including peptide nucleic acid fluo-
rescence in situ hybridization (PNA FISH; AdvanDx, Woburn,
MA) (9, 30), direct germ tube analysis (31, 36), and nucleic
acid detection tests (18, 24), have been developed to enable the
more rapid identification of fungi directly from blood cultures
that have flagged positive. However, these remain reliant on
the sensitivity of the blood culture system.
Efforts to facilitate the earlier diagnosis of fungemia by
direct testing of whole blood, serum, and plasma specimens
have included the application of DNA microarray chips, the
Luminex technology, and the commercial LightCycler Septi-
Fast system (Roche Diagnostics, Mannheim, Germany) (16,
17, 22, 34, 37). Although these tests are highly sensitive, the
clinical utility of these platforms is limited by the lack of stan-
dardization and high setup costs. Furthermore, a significant
proportion of assays target only a small number of pathogens
(Candida albicans, Candida glabrata, Candida krusei, Candida
parapsilosis, and Candida tropicalis) due to the limited multi-
plexing capacities of most real-time PCR instruments. As a
result, other less common but nonetheless important causes of
fungemia, such as other Candida species, Saccharomyces cer-
evisiae, and Fusarium and Scedosporium species are overlooked
(12, 29, 32).
We recently demonstrated the clinical value of a novel, mul-
tiplex-tandem PCR (MT-PCR) platform for the accurate, si-
multaneous identification of up to 16 fungal pathogens from
blood cultures and fungal culture plates (18, 19). The MT-PCR
assay provided rapid (2 h) identification compared with the
time to identification by conventional phenotypic methods. In
the study described here, we sought to determine whether the
time to the detection of candidemia could be expedited by
applying MT-PCR to DNA extracted from whole blood, se-
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rum, and plasma specimens collected up to 5.5 days prior to
and/or up to 14 days subsequent to the time of collection of the
Candida-positive blood sample. The sensitivity of the MT-PCR
with different blood fractions and the impact of technical vari-
ables on DNA isolation and detection were also assessed. The
specificity of the assay was further examined with whole-blood
samples collected from a control cohort of patients considered
to be at high risk of candidemia.
(This work was presented in part at the 48th Interscience
Conference on Antimicrobial Agents and Chemotherapy/In-
fectious Diseases Society of America 46th Annual Meeting,
Washington, DC, 25 to 28 October 2008.)
MATERIALS AND METHODS
Patients. (i) Test population. Two hundred fifty-five whole-blood specimens
collected in 5-ml EDTA-coated tubes were obtained from 109 candidemic pa-
tients. Twenty-nine serum samples were collected from 14 of the candidemic
patients, and 24 plasma specimens were collected from 5 of the candidemic
patients. All specimens were obtained from the Clinical Haematology Labora-
tories of two Australian hospitals (Westmead Hospital, Westmead, New South
Wales, and Princess Alexandra Hospital, Brisbane, Queensland) and from sam-
ples collected as part of the Australian Candidemia Study (3) from August 2001
to July 2009. Approval for the study was obtained from the institutions’ human
research ethics committees.
Specimens retrieved following the diagnosis of candidemia were categorized
into four time (T) points: (i) T 0, blood drawn prior to collection of the positive
blood culture sample; (ii) T  0, blood drawn simultaneously with the collection
of the positive blood culture sample; (iii) T  0, blood drawn after collection of
the positive blood culture sample; and (iv) T  0 flag, blood drawn after the
blood culture had flagged positive. Seven of 39 (18%) patients at T  0, 9 of 43
(21%) patients at T  0, and 39 of 53 (74%) patients at T  0 flag were
receiving antifungal therapy at the time of sampling. Specimens obtained be-
tween 2001 and 2006 were stored at 20°C prior to use. The remaining samples
were stored at 4°C.
(ii) Control population. Seventy-seven whole-blood specimens collected in
EDTA-coated tubes were obtained from 53 medical and surgical intensive care
unit (ICU) patients considered to be at high risk for candidemia (27).
Total nucleic acid extraction. Nucleic acid was extracted in a class II laminar-
flow cabinet, as follows.
(i) Whole blood in EDTA-coated tubes. A High Pure PCR template prepara-
tion kit (Roche Diagnostics, Castle Hill, New South Wales, Australia) was used
to isolate DNA from 3-ml blood samples. Briefly, specimens were divided into
three 1-ml aliquots and washed twice in erythrocyte lysis buffer (0.155 M NH4Cl,
0.01 M NH4HCO3, 0.1 mM EDTA [pH 7.4]) (33) for 10 min at 20°C. A
leukocyte pellet was collected following centrifugation at 4,000  g for 10 min.
Spheroplasts were resuspended in 1 ml molecular biology-grade water (Sigma-
Aldrich, Castle Hill, New South Wales, Australia), vortexed thoroughly, and
centrifuged at 5,400  g for 5 min. The supernatant was removed, and the pellet
was incubated in 300 l tissue lysis buffer and 60 l proteinase K (Roche
Diagnostics) at 55°C for 1 h to overnight. DNA was extracted according to the
manufacturer’s instructions with a final elution volume of 60 l.
(ii) Serum and plasma. Plain and EDTA-coated blood collection tubes were
centrifuged at 1,258  g for 10 min to gather cells; the serum and plasma,
respectively, were then removed. DNA was extracted from a 1-ml sample by
using the protocol for whole blood on a nucliSENS easyMAG instrument (bio-
Me´rieux, Baulkham Hills, New South Wales, Australia) with a final elution
volume of 60 l.
MT-PCR amplification and detection. Master mix reagents and 72-well gene
discs containing lyophilized primers were prepared by AusDiagnostics Pty. Ltd.
(Alexandria, New South Wales, Australia). The fungal ribosomal DNA (rDNA)
internal transcribed spacer 1 (ITS1) and ITS2 regions, elongation factor 1-alpha
(EF1-	), and 
-tubulin gene loci were used to design primers specific for the 10
most frequently encountered Candida species in Australia (3), C. albicans, C.
dubliniensis, C. famata, C. glabrata, C. guilliermondii, C. kefyr, C. krusei, C.
lusitaniae, C. parapsilosis complex (C. parapsilosis, C. metapsilosis, and C. orthop-
silosis), and C. tropicalis, as well as Yarrowia lipolytica, Cryptococcus neoformans
complex (C. neoformans var. grubii, C. neoformans var. neoformans, and Crypto-
coccus gattii), Saccharomyces cerevisiae, Fusarium solani, Fusarium spp., and
Scedosporium prolificans. The primer sequences are not shown due to commer-
cial confidentiality agreements with AusDiagnostics. Product details are avail-
able from AusDiagnostics.
(i) First-round multiplexed preamplification. PCRs were performed in a 20-l
volume consisting of 8 l Step 1 master mix (the composition is commercial and
confidential), 1 U MangoTaq DNA polymerase (Bioline, Alexandria, New South
Wales, Australia) containing 20 U Moloney murine leukemia virus reverse tran-
scriptase (Invitrogen, Mt. Waverly, Victoria, Australia), and 11 l DNA tem-
plate. Amplification was performed on a RotorGene thermal cycler (RG6000;
Qiagen, Doncaster, Victoria, Australia). The thermal cycling conditions were
55°C for 2 min and 95°C for 5 min, followed by 15 cycles of 95°C for 10 s, 60°C
for 20 s, and 72°C for 20 s. The PCRs were monitored for inhibition by the
inclusion of an internal positive control (consisting of artificial DNA) with each
specimen and were monitored for contamination by the inclusion of a negative
water control in each test run.
(ii) Second-round quantification amplification. A total of 5.3 l of each
multiplexed amplification product was diluted into 200 l Step 2 master mix (the
composition is commercial and confidential), 184.5 l molecular biology-grade
water, and 10.1 U MangoTaq DNA polymerase. A 20-l aliquot was then added
to the corresponding 17 positions on the gene disc containing the lyophilized
inner primers. Amplification was performed on the RG6000 thermal cycler. The
cycling conditions were 55°C for 2 min, followed by 30 cycles of 95°C for 1 s, 60°C
for 10 s, and 72°C for 10 s. The fluorescence was measured at the end of each
72°C extension step. Following cycling, a melting curve was generated from 72°C
to 95°C at 0.5°C intervals. The presence or the absence of an organism was
determined by the use of analysis software (AusDiagnostics), which compared
the given melting temperature to the expected melting temperature.
The analytical sensitivity and specificity of the assay were determined previ-
ously (18). The detection limits were 10 CFU/ml of blood for C. albicans, C.
glabrata, C. parapsilosis, and C. tropicalis and 100 CFU/ml of blood for C. krusei.
All primers hybridized specifically with their respective target templates. No
cross-reactions with other clinically relevant organisms were observed (18).
RESULTS
A total of 255 whole-blood specimens in EDTA-coated
tubes, 29 serum specimens, and 24 plasma specimens from 109
patients with candidemia were tested by MT-PCR.
Assay performance compared with that of blood culture.
The performance of the MT-PCR assay was evaluated by using
61 whole-blood samples from 49 patients from whom a blood
sample for culture was drawn simultaneously. For 19 samples
with a positive result by MT-PCR, 18 were positive and 1 was
negative by culture. For 42 samples with a negative result by
MT-PCR, 6 were positive and 36 were negative by culture. The
sensitivity, specificity, positive predictive value (PPV), and neg-
ative predictive value (NPV) of the MT-PCR assay were 75%,
97%, 95%, and 85%, respectively. There was no evidence of
PCR inhibition, as the internal positive control in the MT-PCR
assay for each sample always tested positive.
MT-PCR analysis of whole blood in EDTA-coated tubes,
serum, and plasma samples from patients with documented
candidemia. The results of MT-PCR with whole-blood, serum,
and plasma samples relative to the time of collection of the first
blood sample that flagged positive by culture are illustrated in
Fig. 1. Fungal DNA was detected an average of 2.2 days
(range, 0.5 to 8 days) before the blood cultures signaled posi-
tive for 52/74 (70%) patients, enabling the detection of funge-
mia as well as Candida species identification to be expedited by
up to 4 days (the time required for the blood culture to signal
positive and the time for species identification by use of the
API 32C system [bioMe´rieux]). For 21/39 patients (54%), Can-
dida DNA was detected an average of 1.5 days (range, 0.5 to
4.5 days) prior to the time of collection of the first positive
blood culture sample (T  0). Although the sample numbers
were small, the MT-PCR assay performed better with serum
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(71% positivity rate) and plasma (75%) than with whole blood
(54%). The sensitivities of the MT-PCR with serum, plasma,
and whole-blood samples collected after blood culture positiv-
ity (T  0 flag) and up to 12 days after the blood sample
positive by culture was drawn were 64%, 67%, and 38%, re-
spectively.
Effect of time from T  0 on MT-PCR detection. Whole-
blood samples were collected up to 5.5 days prior to and up to
14 days after T  0. Over this period, the detection of fungal
DNA was the most sensitive with samples collected at T  0
(71%) or within24 h of T 0 (56 to 67%). There was a linear
drop in sensitivity as the time increased from T  0 (Fig. 2).
Fungal species. Of the 109 patients with candidemia, at least
one blood specimen from 66 patients had positive MT-PCR
results. C. albicans was isolated the most frequently (38%),
followed by C. parapsilosis (30%); C. glabrata (14%); C. tropi-
calis (6%); and 1.5% each of C. krusei, C. kefyr, C. neoformans
complex, and S. cerevisiae. Four patients had candidemia due
to two Candida species: two patients had mixed C. albicans and
C. glabrata infections and one patient each had mixed C. dub-
liniensis and C. parapsilosis infections and C. glabrata and C.
tropicalis infections. The results of molecular- and culture-
based species identification were concordant for 61 of 66
(92%) patients. In one case, C. albicans was phenotypically
identified incorrectly as C. dubliniensis: MT-PCR confirmed
that the original culture isolate was C. albicans. Discrepant
identification (phenotypic versus MT-PCR identifications) for
the remaining four cases was noted with C. albicans and C.
tropicalis, Candida nivariensis and C. albicans, C. glabrata and
C. parapsilosis, and C. parapsilosis and C. albicans. Phenotypic
identification was confirmed by MT-PCR with the original
culture isolate. With culture as the gold standard, MT-PCR
yielded a single incorrect result, which was consistent on repeat
MT-PCR analysis of the positive specimen.
MT-PCR results for paired blood and serum samples and
paired blood and plasma samples. Paired whole-blood and
serum samples (n  22 samples from 14 patients) and whole-
blood and plasma samples (n  14 samples from 5 patients)
were tested by MT-PCR. Concordant positive or negative MT-
PCR results were obtained for 50% of the blood-serum sample
pairs and 79% of the blood-plasma sample pairs. For whole-
blood negative cases, MT-PCR performed better with serum
specimens (50%) than with plasma specimens (7%), although
the results were not statistically significant, given the small
number of samples tested (Table 1). On a patient basis, the
assay was positive with sera obtained from five of six (83%)
patients with positive whole-blood samples and seven of eight
(88%) patients with negative whole-blood samples. The assay
was also positive for concurrently drawn whole-blood and plasma
samples obtained from four of five (80%) patients. Eight of nine
(89%) patients not receiving antifungal therapy had MT-PCR-
positive sera, while three of four (75%) patients not receiving
antifungal therapy had positive plasma samples. For one patient
with a mixed infection, both C. glabrata and C. tropicalis were
detected in the patient’s plasma, whereas only C. glabrata was
detected in the patient’s serum and whole blood.
MT-PCR of whole-blood samples from high-risk control
patients. Only 1 of 77 whole-blood samples collected from the
control group of patients at high risk of developing an invasive
fungal infection tested positive by MT-PCR. Repeat testing of
the same specimen confirmed the presence of C. kefyr DNA;
all other samples were negative by MT-PCR. All control pa-
tients remained without documented candidemia during the
relevant episode of hospitalization.
Effect of specimen storage on MT-PCR performance. Spec-
imens collected between 2001 and 2006 were stored at 20°C
prior to DNA extraction, and those collected in 2007 were kept
at 4°C prior to DNA extraction. Samples obtained in 2008 and
2009 were also stored at 4°C, but DNA was extracted within 1
week of specimen acquisition. Figure 3 shows the MT-PCR
data for 85 specimens (from 62 patients) that were collected
within 24 h of the time that the blood sample positive by
culture was drawn. Overall, the detection rate by MT-PCR was
64%. The assay performed best with whole-blood samples that
were stored frozen (75%) rather than those that were stored at
FIG. 1. Results of MT-PCR detection for 109 candidemic patients
which have been stratified for time of collection relative to the time of
collection of the first blood sample that flagged positive by culture
(T  0); i.e., those obtained before the time of collection of the blood
sample that flagged positive by blood culture (BC) (T  0), simulta-
neously with the time of collection of the blood sample that flagged
positive by blood culture (T  0), or after collection of the blood
sample that flagged positive by blood culture (T  0). T  0 flag,
blood samples drawn after the blood culture had flagged positive.ve,
positive; WB, whole blood. Note that samples were collected from
some patients at multiple time points.
FIG. 2. Percentage of MT-PCR-positive whole-blood samples
stratified by collection times relative to the time that the first positive
blood culture (BC) sample was drawn (T  0) for 255 specimens
collected from 109 candidemic patients.
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4°C (56%) for extended periods (6 to 9 months). The rate of
detection improved by 10% when DNA was extracted from
fresh samples (1 week old).
DISCUSSION
The limitations of conventional blood culture systems for the
detection of fungemia have prompted the need to develop
alternative rapid, sensitive, and accurate methods. We have
previously demonstrated the value of the fungal MT-PCR as-
say for the rapid identification of Candida spp. from blood
cultures that had signaled positive and demonstrated yeasts on
Gram stain (18). MT-PCR performed better than blood cul-
ture with DNA extracted from whole blood for 52/74 (70%)
patients, accelerating the time to detection and identification
of the pathogenic species by up to 4 days.
The performance of the MT-PCR assay was first assessed
with whole-blood samples drawn simultaneously with the pos-
itive blood culture sample. Fungal cells are estimated to cir-
culate in the blood at levels of10 CFU/ml, with 25% of cases
having 1 CFU/ml (38). A low fungal load at the time of
sampling, the intermittent hepatic clearance of fungal cells
from blood, and/or the short life of circulating DNA (2, 4) may
have contributed to the lower sensitivity (75%) and NPV
(85%) reported in this study. The single MT-PCR-positive/
culture-negative result for C. kefyr (97% specificity) is not
necessarily a false-positive result since nonviable cells or insuf-
ficient numbers of cells may have been present in the blood
inoculated for culture. Furthermore, the sensitivities of blood
culture systems are known to be poor even when viable cells
are inoculated into the bottle (11).
The rate of concordance between MT-PCR and culture
identification was high (92%; n  66 samples). Concurrent
infections with two species of Candida were also identified by
MT-PCR of blood from 4 patients, and the fungal species in 11
patients with combined bacteremia and fungemia were cor-
rectly identified. Discrepant results were obtained for a single
sample from each of five patients. In one case, the phenotypic
misidentification of C. albicans was made (C. dubliniensis by
culture), highlighting the difficulty of differentiating these two
closely related species by standard methods (35). The remain-
ing discrepancies are unlikely to have been due to cross-reac-
tions of primer sequences since none were observed when the
primers were tested with 500 culture isolates and blood cul-
ture specimens (18, 19). Contamination of the sample (e.g.,
during routine hematological examination) prior to DNA ex-
traction is a plausible explanation.
There is currently no consensus on the optimal blood frac-
tion from which to isolate fungal DNA (21). Although small
numbers of paired samples were tested, we detected Candida
DNA more often in serum (71%) and plasma (75%) than in
whole blood (56%) (Fig. 1), as has been observed in other
studies (1, 14, 23). It has been demonstrated in rabbit models
that free DNA (in the serum and plasma fractions) is cleared
more slowly than intracellular DNA, and the efficiency of ex-
traction of fungal DNA from plasma or serum is higher than
that from whole blood (1, 14). Although whole blood contains
both free and cell-associated fungal DNA, all fungal DNA
except that associated with leukocytes and/or whole fungal
cells is removed during the process of red blood cell lysis and
the removal of PCR inhibitors. In one study, a 50% loss of C.
albicans DNA was noted following the centrifugation and re-
moval of erythrocytes (13). Notably, the time needed to extract
DNA from serum and plasma (1 h) was significantly shorter
and less laborious than that needed to extract DNA from
whole blood (at least 4 h), since cell lysis was not required. The
optimal blood fraction for the isolation of DNA of pathogenic
molds is less well studied but can be expected to differ from
that of yeasts due to differences in cell wall composition/struc-
ture and DNA kinetics (20, 40).
The sensitivity of DNA detection may also vary with the time
of blood sampling during the course of the infection (23).
MT-PCR was more likely to be positive when it was performed
with whole blood collected within24 h of T 0 (Fig. 2). One
possible explanation for the lower yield at T  0 is the absence
of infection, since candidemia is usually acute in onset. We
considered whether the reduced sensitivity of the MT-PCR
assay with whole-blood specimens at T  0 was due to anti-
fungal therapy, which can be expected to release DNA from
damaged fungal cells, thereby favoring the detection of DNA
in serum and plasma samples. Our results did not support this
hypothesis since the serum and plasma samples from 89% and
75% of patients, respectively, who had not received antifungal
TABLE 1. MT-PCR results for paired whole-blood and serum samples and paired whole-blood and plasma samples
Samples
No. (%) of paired samples with the following MT-PCR results:
WBa and serum or
plasma positive
WB positive and serum
or plasma negative
WB negative and serum
or plasma positive
WB and serum or
plasma negative
WB and serum (n  22, 14 patients) 8 (36) 0 (0) 11 (50) 3 (14)
WB and plasma (n  14, 5 patients) 8 (57) 2 (14) 1 (7) 3 (22)
a WB, whole blood.
FIG. 3. Effect of storage on MT-PCR detection of fungi from 85
whole-blood specimens from 62 candidemic patients.
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agents at or before the time of sampling were MT-PCR posi-
tive. Since DNA from both viable and nonviable cells is de-
tected by MT-PCR, the results used to make clinical decisions
should always be interpreted in combination with other micro-
biological data.
Our results also indicate that the temperature and duration
of specimen storage can affect the sensitivity of MT-PCR (Fig.
3). The MT-PCR assay performed the best (75% sensitive)
with whole-blood samples stored at 20°C. Freeze-thaw cycles
may help disrupt the integrity of the fungal cell wall, leading to
the better recovery of DNA. On the basis of these results, we
propose that samples be stored at 20°C until they are pro-
cessed to optimize the sensitivity of the assay.
The MT-PCR platform employed in the present study has a
major advantage over other real-time multiplexing platforms
(e.g., microarrays and the Luminex technology), in that it does
not require expensive or specialized equipment (e.g., a flow
cytometer), as it utilizes Evagreen dye and melting curve anal-
ysis for species identification. Flexibility in the number of de-
tection targets also enables the number of samples that can be
tested in a single run to be varied, and the platform can be
automated for use by laboratory staff with little experience with
molecular processing and analysis. The costs are similar to
those of current laboratory tests at $14 per sample and 30 min
of labor cost per test run. The assay had a detection limit of 10
CFU/ml for the major Candida species (except C. krusei, for
which the detection limit is 100 CFU/ml), which compares favor-
ably to that of the LightCycler SeptiFast system (30 CFU/ml;
Roche Diagnostics).
The results demonstrate that MT-PCR is capable of provid-
ing results within a single working day (including DNA extrac-
tion, PCR amplification, and analysis). Its clinical utility, how-
ever, is dependent in part on the frequency of the test runs. We
envisage this assay to be performed thrice weekly in our lab-
oratory. Taking into consideration the potential delays in spec-
imen transport and handling, we anticipate that the diagnosis
of candidemia would realistically be expedited by 1 to 2 days
(compared with the times for blood culture detection and
species identification by use of the API 32C system [bio-
Me´rieux]). Even so, this compares favorably or is similar to the
turnaround times of other rapid identification methods, such
as PNA FISH techniques or rapid trehalose tests (RTTs),
which require either the flagging of a blood culture or a pure
culture of Candida. Furthermore, the MT-PCR assay has
the advantage of enabling the species identification of a
large range of species (n  16). The Yeast Traffic Light PNA
FISH protocol enables group identification of C. albicans/C.
parapsilosis, C. glabrata/C. krusei, and C. tropicalis but does
not select for each species (www.advandx.com), while the
RTT selectively identifies only C. glabrata (6).
A limitation of this assay was that it was unable to detect
fungal DNA in six (25%) whole-blood specimens drawn simul-
taneously with the positive blood culture sample. We therefore
propose that the platform be used to complement blood cul-
ture until large-scale clinical evaluations are performed to po-
sition the role of MT-PCR in the diagnostic laboratory. None-
theless, the diagnosis of candidemia and the identity of the
pathogen were available earlier for the remaining 75% of the
patients. Another limitation was the nonsystematic collection
and storage of samples, given the retrospective nature of this
study. This methodology was used since it was the most effi-
cient way to assess the potential utility of the MT-PCR assay
for the early diagnosis of candidemia. Whole-blood samples
were primarily collected for routine hematological examina-
tion. As such, blood samples for culture were simultaneously
drawn from few patients at the earlier time points, presumably
because there was no clinical evidence of sepsis. It is therefore
possible that the higher rate of MT-PCR positivity was driven
by the more frequent sampling of whole-blood specimens. De-
spite these limitations, a proof of principle was established and
important data on technical variables (e.g., specimen type and
storage conditions) were ascertained.
In conclusion, the MT-PCR assay presents a promising plat-
form for the real-time screening and potentially earlier diag-
nosis of candidemia. Our results additionally suggest that se-
rum and plasma samples are preferable to whole blood,
although a greater number of paired specimens need to be
tested. Pending further interlaboratory validation and studies
with samples from a larger patient cohort, the platform should
be used in conjunction with blood culture. Although molds
were not tested in the present study, the MT-PCR assay offers
the potential for the early detection of BSIs with molds such as
Fusarium spp. and S. prolificans. Further prospective studies
are warranted to determine the extent to which the early de-
tection of candidemia affects clinical practice.
ACKNOWLEDGMENTS
We thank the Australian Candidemia Study for access to 38 blood
samples and for providing data on antifungal therapy. We also thank
the staff of the Clinical Haematology Laboratories at Westmead Hos-
pital and Princess Alexandra Hospital for assistance with the provision
of whole-blood specimens in EDTA-coated tubes and Dani Goh and
Martin Cullen for help in identifying appropriate control patients.
This work was supported in part by a Centre for Clinical Research
Excellence grant (grant no. 264625) from the National Health and
Medical Research Council of Australia. A.L. is supported by an Aus-
tralian Postgraduate Award.
REFERENCES
1. Bougnoux, M., C. Dupont, J. Mateo, P. Saulnier, V. Faivre, D. Payen, and M.
Nicolas-Chanoine. 1999. Serum is more suitable than whole blood for diag-
nosis of systemic candidiasis by nested PCR. J. Clin. Microbiol. 37:925–930.
2. Bretagne, S., J. M. Costa, E. Bart-Delabesse, N. Dhedin, C. Rieux, and C.
Cordonnier. 1998. Comparison of serum galactomannan antigen detection
and competitive polymerase chain reaction for diagnosing invasive aspergil-
losis. Clin. Infect. Dis. 26:1407–1412.
3. Chen, S., M. Slavin, Q. Nguyen, D. Marriott, E. G. Playford, D. Ellis, T.
Sorrell, and Australian Candidemia Study. 2006. Active surveillance for
candidemia, Australia. Emerg. Infect. Dis. 12:1508–1516.
4. de Repentigny, L. 1992. Serodiagnosis of candidiasis, aspergillosis, and cryp-
tococcosis. Clin. Infect. Dis. 14(Suppl. 1):S11–S22.
5. Fluit, A. C., M. E. Jones, F. J. Schmitz, J. Acar, R. Gupta, and J. Verhoef.
2000. Antimicrobial susceptibility and frequency of occurrence of clinical
blood isolates in Europe from the SENTRY antimicrobial surveillance pro-
gram, 1997 and 1998. Clin. Infect. Dis. 30:454–460.
6. Freydiere, A. M., J. D. Perry, O. Faure, B. Willinger, A. M. Tortorano, A.
Nicholson, J. Peman, and P. E. Verweij. 2004. Routine use of a commercial
test, GLABRATA RTT, for rapid identification of Candida glabrata in six
laboratories. J. Clin. Microbiol. 42:4870–4872.
7. Fridkin, S. K. 2005. The changing face of fungal infections in health care
settings. Clin. Infect. Dis. 41:1455–1460.
8. Garey, K. W., M. Rege, M. P. Pai, D. E. Mingo, K. J. Suda, R. S. Turpin, and
D. T. Bearden. 2006. Time to initiation of fluconazole therapy impacts
mortality in patients with candidemia: a multi-institutional study. Clin. In-
fect. Dis. 43:25–31.
9. Gherna, M., and W. G. Merz. 2009. Identification of Candida albicans and
Candida glabrata within 1.5 hours directly from positive blood culture bottles
with a shortened peptide nucleic acid fluorescence in situ hybridization
protocol. J. Clin. Microbiol. 47:247–248.
10. Gudlaugsson, O., S. Gillespie, K. Lee, J. Vande Berg, J. Hu, S. Messer, L.
VOL. 48, 2010 EARLY DIAGNOSIS OF CANDIDEMIA 815
 o
n
 O
ctober 21, 2015 by UQ Library
http://jcm.asm.org/
D
ow
nloaded from
 
Herwaldt, M. Pfaller, and D. Diekema. 2003. Attributable mortality of
nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172–1177.
11. Horvath, L. L., D. R. Hospenthal, C. K. Murray, and D. P. Dooley. 2003.
Detection of simulated candidemia by the BACTEC 9240 system with plus
aerobic/F and anaerobic/F blood culture bottles. J. Clin. Microbiol. 41:4714–
4717.
12. Jensen, T. G., B. Gahrn-Hansen, M. Arendrup, and B. Bruun. 2004. Fusar-
ium fungaemia in immunocompromised patients. Clin. Microbiol. Infect.
10:499–501.
13. Jordan, J. A. 1994. PCR identification of four medically important Candida
species by using a single primer pair. J. Clin. Microbiol. 32:2962–2967.
14. Kasai, M., A. Francesconi, R. Petraitiene, V. Petraitis, A. M. Kelaher, H. S.
Kim, J. Meletiadis, T. Sein, J. Bacher, and T. J. Walsh. 2006. Use of
quantitative real-time PCR to study the kinetics of extracellular DNA re-
leased from Candida albicans, with implications for diagnosis of invasive
candidiasis. J. Clin. Microbiol. 44:143–150.
15. Kontoyiannis, D., V. Wessel, G. Bodey, et al. 2000. Zygomycosis in the 1990s
in a tertiary care centre. Clin. Infect. Dis. 30:851–856.
16. Landlinger, C., S. Preuner, B. Willinger, B. Haberpursch, Z. Racil, J. Mayer,
and T. Lion. 2009. Species-specific identification of a wide range of clinically
relevant fungal pathogens by use of Luminex xMAP technology. J. Clin.
Microbiol. 47:1063–1073.
17. Lau, A., S. Chen, S. Sleiman, and T. Sorrell. 2009. Current status and future
perspectives of molecular and serological methods in diagnostic mycology.
Future Microbiol. 4:1185–1222.
18. Lau, A., T. C. Sorrell, S. Chen, K. Stanley, J. Iredell, and C. Halliday. 2008.
Multiplex tandem PCR: a novel platform for rapid detection and identifica-
tion of fungal pathogens from blood culture specimens. J. Clin. Microbiol.
46:3021–3027.
19. Lau, A., T. C. Sorrell, O. Lee, K. Stanley, and C. Halliday. 2008. Colony
multiplex-tandem PCR for rapid, accurate identification of fungal cultures.
J. Clin. Microbiol. 46:4058–4060.
20. Loeffler, J., H. Hebart, U. Brauchle, U. Schumacher, and H. Einsele. 2000.
Comparison between plasma and whole blood specimens for detection of
Aspergillus DNA by PCR. J. Clin. Microbiol. 38:3830–3833.
21. Maaroufi, Y., N. Ahariz, M. Husson, and F. Crokaert. 2004. Comparison of
different methods of isolation of DNA of commonly encountered Candida
species and its quantitation by using a real-time PCR-based assay. J. Clin.
Microbiol. 42:3159–3163.
22. McMullan, R., L. Metwally, P. V. Coyle, S. Hedderwick, B. McCloskey, H. J.
O’Neill, C. C. Patterson, G. Thompson, C. H. Webb, and R. J. Hay. 2008. A
prospective clinical trial of a real-time polymerase chain reaction assay for
the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin.
Infect. Dis. 46:890–896.
23. Metwally, L., D. J. Fairley, P. V. Coyle, R. J. Hay, S. Hedderwick, B. Mc-
Closkey, H. J. O’Neill, C. H. Webb, and R. McMullan. 2008. Comparison of
serum and whole-blood specimens for the detection of Candida DNA in
critically ill, non-neutropenic patients. J. Med. Microbiol. 57:1269–1272.
24. Metwally, L., G. Hogg, P. V. Coyle, R. J. Hay, S. Hedderwick, B. McCloskey,
H. J. O’Neill, G. M. Ong, G. Thompson, C. H. Webb, and R. McMullan.
2007. Rapid differentiation between fluconazole-sensitive and -resistant spe-
cies of Candida directly from positive blood-culture bottles by real-time
PCR. J. Med. Microbiol. 56:964–970.
25. Morgan, J., M. I. Meltzer, B. D. Plikaytis, A. N. Sofair, S. Huie-White, S.
Wilcox, L. H. Harrison, E. C. Seaberg, R. A. Hajjeh, and S. M. Teutsch. 2005.
Excess mortality, hospital stay, and cost due to candidemia: a case-control
study using data from population-based candidemia surveillance. Infect.
Control Hosp. Epidemiol. 26:540–547.
26. Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying the empiric
treatment of Candida bloodstream infection until positive blood culture
results are obtained: a potential risk factor for hospital mortality. Antimi-
crob. Agents Chemother. 49:3640–3645.
27. Ostrosky-Zeichner, L., C. Sable, J. Sobel, B. D. Alexander, G. Donowitz, V.
Kan, C. A. Kauffman, D. Kett, R. A. Larsen, V. Morrison, M. Nucci, P. G.
Pappas, M. E. Bradley, S. Major, L. Zimmer, D. Wallace, W. E. Dismukes,
and J. H. Rex. 2007. Multicenter retrospective development and validation of
a clinical prediction rule for nosocomial invasive candidiasis in the intensive
care setting. Eur. J. Clin. Microbiol. Infect. Dis. 26:271–276.
28. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidi-
asis: a persistent public health problem. Clin. Microbiol. Rev. 20:133–163.
29. Pietrucha-Dilanchian, P., R. E. Lewis, H. Ahmad, and A. E. Lechin. 2001.
Candida lusitaniae catheter-related sepsis. Ann. Pharmacother. 35:1570–
1574.
30. Shepard, J. R., R. M. Addison, B. D. Alexander, P. Della-Latta, M. Gherna,
G. Haase, G. Hall, J. K. Johnson, W. G. Merz, H. Peltroche-Llacsahuanga,
H. Stender, R. A. Venezia, D. Wilson, G. W. Procop, F. Wu, and M. J.
Fiandaca. 2008. Multicenter evaluation of the Candida albicans/Candida
glabrata peptide nucleic acid fluorescent in situ hybridization method for
simultaneous dual-color identification of C. albicans and C. glabrata directly
from blood culture bottles. J. Clin. Microbiol. 46:50–55.
31. Sheppard, D. C., M. C. Locas, C. Restieri, and M. Laverdiere. 2008. Utility
of the germ tube test for direct identification of Candida albicans from
positive blood culture bottles. J. Clin. Microbiol. 46:3508–3509.
32. Simarro, E., F. Marin, A. Morales, E. Sanz, J. Perez, and J. Ruiz. 2001.
Fungemia due to Scedosporium prolificans: a description of two cases with
fatal outcome. Clin. Microbiol. Infect. 7:645–647.
33. Skladny, H., D. Buchheidt, C. Baust, F. Krieg-Schneider, W. Seifarth, C.
Leib-Mosch, and R. Hehlmann. 1999. Specific detection of Aspergillus spe-
cies in blood and bronchoalveolar lavage samples of immunocompromised
patients by two-step PCR. J. Clin. Microbiol. 37:3865–3871.
34. Spiess, B., W. Seifarth, M. Hummel, O. Frank, A. Fabarius, C. Zheng, H.
Morz, R. Hehlmann, and D. Buchheidt. 2007. DNA microarray-based de-
tection and identification of fungal pathogens in clinical samples from neu-
tropenic patients. J. Clin. Microbiol. 45:3743–3753.
35. Sullivan, D., and D. Coleman. 1998. Candida dubliniensis: characteristics and
identification. J. Clin. Microbiol. 36:329–334.
36. Terlecka, J. A., P. A. du Cros, C. Orla Morrissey, and D. Spelman. 2007.
Rapid differentiation of Candida albicans from non-albicans species by germ
tube test directly from BacTAlert blood culture bottles. Mycoses 50:48–51.
37. Westh, H., G. Lisby, F. Breysse, B. Boddinghaus, M. Chomarat, V. Gant, A.
Goglio, A. Raglio, H. Schuster, F. Stuber, H. Wissing, and A. Hoeft. 2009.
Multiplex real-time PCR and blood culture for identification of bloodstream
pathogens in patients with suspected sepsis. Clin. Microbiol. Infect. 15:544–
551.
38. White, P. L., A. Shetty, and R. A. Barnes. 2003. Detection of seven Candida
species using the Light-Cycler system. J. Med. Microbiol. 52:229–238.
39. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and
M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals:
analysis of 24,179 cases from a prospective nationwide surveillance study.
Clin. Infect. Dis. 39:309–317.
40. Yamakami, Y., A. Hashimoto, I. Tokimatsu, and M. Nasu. 1996. PCR de-
tection of DNA specific for Aspergillus species in serum of patients with
invasive aspergillosis. J. Clin. Microbiol. 34:2464–2468.
816 LAU ET AL. J. CLIN. MICROBIOL.
 o
n
 O
ctober 21, 2015 by UQ Library
http://jcm.asm.org/
D
ow
nloaded from
 
